Providing independent clinical excellence since 2005
Bempedoic acid offers a new avenue for patients who require an alternative to statins for managing high cholesterol. Its liver-specific action and excellent safety and side effect profile make it a valuable addition to available treatments we can use to combat high LDL cholesterol levels to reduce coronary inflammation and stabilise high risk coronary plaque.
For patients who have been diagnosed with an acute coronary syndrome, requiring bypass surgery or stent, or have CT Angiography and or raised FAI, the latest European and UK guidelines reflect the finding that there is no lower limit for LDL yet discovered, basically meaning the lower the better. These recommendations come after new trials with lower targets showed better outcomes. As a result, millions of people around the world need to be looking more carefully at whether they are taking sufficient medication to lower their LDL to these new targets, for the very best outcomes to be achieved.
Being born with almost no circulating cholesterol (or reduction of LDL to zero by drugs) results in nothing except a zero-lifetime risk of atherosclerosis (or cessation and reduction in atherosclerosis).